Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: A link between coagulation and inflammation

Blood

Volumn 114, Issue 13, 2009, Pages 2812-2818

  Kastl, Stefan P ^a,b   Speidl, Walter S ^a   Katsaros, Katharina M ^a   Kaun, Christoph ^a   Rega, Gersina ^a   Assadian, Afshin ^c   Hagmueller, Georg W ^c   Hoeth, Martina ^a   De Martin, Rainer ^a   Ma, Yongsheng ^d   Maurer, Gerald ^a   Huber, Kurt ^c   Wojta, Johann ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

^c WILHELMINEN HOSPITAL   (Austria)

^d Nucl Eng Idaho State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ONCOSTATIN M; PROTEIN C JUN; PROTEINASE ACTIVATED RECEPTOR 1; SYNAPTOPHYSIN; THROMBIN; TRANSCRIPTION FACTOR AP 1;

ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INFLAMMATION; MACROPHAGE; MONOCYTE; ONCOGENE C FOS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION; BLOOD; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; PROMOTER REGION; TRANSCRIPTION INITIATION;

BLOOD COAGULATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MACROPHAGES; MITOGEN-ACTIVATED PROTEIN KINASE 3; MONOCYTES; ONCOSTATIN M; PROMOTER REGIONS, GENETIC; RECEPTOR, PAR-1; THROMBIN; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTIONAL ACTIVATION;

EID: 70350497166     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-200915     Document Type: Article

References (47)

1. Cavaillon JM. Cytokines and macrophages. Biomed Pharmacother. 1994;48(10):445-453.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340(2):115-126.
3. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92(3):657-671.
4. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet. 1999;353(suppl 2):SII5-SII9.
5. Libby P. Changing concepts of atherogenesis. J Intern Med. 2000;247(3):349-358.
6. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J. 2004;25(14):1197-1207. (Pubitemid 38891569)
7. Viles-Gonzalez JF, Fuster V, Badimon JJ. Links between inflammation and thrombogenicity in atherosclerosis. Curr Mol Med. 2006;6(5):489-499.
8. Willeit J, Kiechl S, Oberhollenzer F, et al. Distinct risk profiles of early and advanced atherosclerosis: prospective results from the Bruneck Study. Arterioscler Thromb Vasc Biol. 2000;20(2):529-537. (Pubitemid 30086113)
9. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3(8):1800-1814. (Pubitemid 41716567)
10. Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2007;27(1):27-36. (Pubitemid 46370476)
11. Bar-Shavit R, Kahn A, Fenton JW II, Wilner GD. Chemotactic response of monocytes to thrombin. J Cell Biol. 1983;96(1):282-285.
12. Colotta F, Sciacca FL, Sironi M, Luini W, Rabiet MJ, Mantovani A. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol. 1994;144(5):975-985. (Pubitemid 24160638)
13. Sower LE, Froelich CJ, Allegretto N, Rose PM, Hanna WD, Klimpel GR. Extracellular activities of human granzyme A: monocyte activation by granzyme A versus alpha-thrombin. J Immunol. 1996;156(7):2585-2590. (Pubitemid 26093702)
14. Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol. 2007;14(1):55-61.
15. Jones A, Geczy CL. Thrombin and factor Xa enhance the production of interleukin-1. Immunology. 1990;71(2):236-241. (Pubitemid 20341224)
16. Naldini A, Sower L, Bocci V, Meyers B, Carney DH. Thrombin receptor expression and responsiveness of human monocytic cells to thrombin is linked to interferon-induced cellular differentiation. J Cell Physiol. 1998;177(1):76-84. (Pubitemid 28421523)
17. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol. 2001;88(8A):10K-15K. (Pubitemid 33016744)
18. Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002;99(3):1053-1059.
19. Chen SH, Benveniste EN. Oncostatin M: a pleiotropic cytokine in the central nervous system. Cytokine Growth Factor Rev. 2004;15(5):379-391. (Pubitemid 39144383)
20. Ensoli F, Fiorelli V, DeCristofaro M, et al. Inflammatory cytokines and HIV-1-associated neurodegeneration: oncostatin-M produced by mononuclear cells from HIV-1-infected individuals induces apoptosis of primary neurons. J Immunol. 1999;162(10):6268-6277. (Pubitemid 29314992)
21. Hasegawa M, Sato S, Ihn H, Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology (Oxford). 1999;38(7):612-617. (Pubitemid 29507328)
22. Pelletier JP, Martel-Pelletier J. Oncostatin M: foe or friend? Arthritis Rheum. 2003;48(12):3301-3303.
23. Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol. 2003;149:39-52.
24. Zarling JM, Shoyab M, Marquardt H, Hanson MB, Lioubin MN, Todaro GJ. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci U S A. 1986;83(24):9739-9743. (Pubitemid 17223432)
25. Demyanets S, Kaun C, Rychli K, et al. The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways. Am J Physiol Heart Circ Physiol. 2007;293(3):H1962-H1968. (Pubitemid 47367248)
26. Grove RI, Eberhardt C, Abid S, et al. Oncostatin M is a mitogen for rabbit vascular smooth muscle cells. Proc Natl Acad Sci U S A. 1993;90(3):823-827. (Pubitemid 23053902)
27. Nagata T, Kai H, Shibata R, Koga M, Yoshimura A, Imaizumi T. Oncostatin M, an interleukin-6 family cytokine, upregulates matrix metalloproteinase- 9 through the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cultured smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23(4):588-593. (Pubitemid 36438070)
28. Shioi A, Katagi M, Okuno Y, et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. Circ Res. 2002;91(1):9-16. (Pubitemid 34778936)
29. Nishibe T, Parry G, Ishida A, et al. Oncostatin M promotes biphasic tissue factor expression in smooth muscle cells: evidence for Erk-1/2 activation. Blood. 2001;97(3):692-699. (Pubitemid 32113402)
30. Goebeler M, Yoshimura T, Toksoy A, Ritter U, Brocker EB, Gillitzer R. The chemokine repertoire of human dermal microvascular endothelial cells and its regulation by inflammatory cytokines. J Invest Dermatol. 1997;108(4):445-451. (Pubitemid 27148279)
31. Pourtau J, Soria C, Paysant J, Vannier JP, Vasse M. In-vitro effect of oncostatin M on the release by endothelial cells of von Willebrand factor, tissue-type plasminogen activator and plasminogen activator inhibitor-1. Blood Coagul Fibrinolysis. 1998;9(7):609-615. (Pubitemid 28520158)
32. Middleton RK, Lloyd GM, Bown MJ, Cooper NJ, London NJ, Sayers RD. The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: a protein array study. J Vasc Surg. 2007;45(3):574-580.
33. Modur V, Feldhaus MJ, Weyrich AS, et al. Oncostatin M is a proinflammatory mediator: in vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest. 1997;100(1):158-168. (Pubitemid 27311254)
34. Vasse M, Pourtau J, Trochon V, et al. Oncostatin M induces angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol. 1999;19(8):1835-1842. (Pubitemid 29379912)
35. Speidl WS, Toller WG, Kaun C, et al. Catecholamines potentiate LPS-induced expression of MMP-1 and MMP-9 in human monocytes and in the human monocytic cell line U937: possible implications for peri-operative plaque instability. FASEB J. 2004;18(3):603-605.
36. Steiner S, Seidinger D, Huber K, Kaun C, Minar E, Kopp CW. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression. Arterioscler Thromb Vasc Biol. 2003;23(9):1697-1702. (Pubitemid 37108219)
37. Kastl SP, Speidl WS, Kaun C, et al. The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-kappaB activation. J Thromb Haemost. 2006;4(8):1790-1797. (Pubitemid 44144807)
38. Kastl SP, Speidl WS, Kaun C, et al. In human macrophages the complement component C5a induces the expression of oncostatin M via AP-1 activation. Arterioscler Thromb Vasc Biol. 2008;28(3):498-503.
39. Ma Y, Streiff RJ, Liu J, Spence MJ, Vestal RE. Cloning and characterization of human oncostatin M promoter. Nucleic Acids Res. 1999;27(23):4649-4657.
40. Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost. 2007;98(1):234-242. (Pubitemid 47074201)
41. Chen D, Carpenter A, Abrahams J, et al. Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo. J Exp Med. 2008;205(8):1739-1746.
42. Chiu YC, Fong YC, Lai CH, et al. Thrombin-induced IL-6 production in human synovial fibroblasts is mediated by PAR1, phospholipase C, protein kinase C alpha, c-Src, NF-kappa B and p300 pathway. Mol Immunol. 2008;45(6):1587-1599.
43. Tabibiazar R, Wagner RA, Ashley EA, et al. Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary disease. Physiol Genomics. 2005;22(2):213-226. (Pubitemid 41356355)
44. Brummel-Ziedins KE, Pouliot RL, Mann KG. Thrombin generation: phenotypic quantitation. J Thromb Haemost. 2004;2(2):281-288.
45. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev. 2001;53(2):245-282.
46. Martorell L, Martinez-Gonzalez J, Rodriguez C, Gentile M, Calvayrac O, Badimon L. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost. 2008;99(2):305-315. (Pubitemid 351230960)
47. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003;3(11):859-868.